Cancer drug cabozantinib tested in kids and young adults with bone cancer
NCT ID NCT06341712
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug cabozantinib in children, teens, and young adults with osteosarcoma (a bone cancer) that could not be fully removed by surgery. Participants who had stable or partially improved disease after chemotherapy received either cabozantinib plus best supportive care or best supportive care alone. The goal was to see if cabozantinib could delay cancer progression. The trial was terminated early and enrolled only 10 people, so its findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib (a cancer drug taken as a tablet)
What this could lead to
If it works, this could offer a way to delay cancer growth in young people with osteosarcoma that cannot be surgically removed.
What could go wrong
This trial was terminated early with only 10 participants, so results are very limited. Cabozantinib may cause side effects like fatigue, diarrhea, or high blood pressure, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Città della Salute e della Scienza di Torino
Piemonte, Italy
-
Amsterdam UMC - Locatie AMC
Amsterdam, Netherlands
-
Birmingham Children's Hospital
Birmingham, United Kingdom
-
Centre Oscar Lambret
Lille, France
-
Children's Hospital of the King's Daughters
Norfolk, Virginia, 23507, United States
-
Dr. von Haunerschen Kinderspital
München, Germany
-
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Hospital de La Santa Creu i Sant Pau
Barcelona, Spain
-
Instytut Matki i Dziecka
Warsaw, Poland
-
McGill University Health Centre - Centre for Innovative Medicine
Québec, Canada
-
Ospedale Ortopedico Rizzoli di Bologna
Bologna, Italy
-
Princess Margaret cancer center
Toronto, Canada
-
University Hospital Gent
Ghent, Belgium
-
Universitätsmedizin Mainz
Mainz, Germany